1/37
Comprehensive vocabulary flashcards covering DNA replication safeguards, DNA repair pathways, hereditary repair disorders, classifications of mutations and polymorphisms, pharmacogenomics, heterozygote advantage, and clinical variant classification standards.
Initial nucleotide selection
The first safeguard during DNA replication where polymerase selects incoming bases, exhibiting an error rate of approximately 1 in 105 where an incorrect nucleotide may be inserted.
Proofreading during replication
The second safeguard during replication in which 3′→5′ exonuclease activity removes most mismatched nucleotides, bringing the error rate to approximately 1 in 107.
Mismatch repair (MMR)
A post-replication repair pathway that removes most remaining mismatches (such as A-G and T-C mismatches, base insertions, and base deletions), reducing the final error rate to approximately 1 in 109–1010.
Base-excision repair (BER)
A DNA repair pathway that fixes abnormal bases, base adducts, single-strand breaks, and abasic sites caused by X-rays, alkylating agents, hydrolysis, and O2 radicals.
Nucleotide-excision repair (NER)
A DNA repair pathway that removes bulky adducts and thymidine dimers induced by UV irradiation and chemical mutagens.
Recombination repair (HR, EJ)
A repair pathway comprising homologous recombination and end-joining that repairs double-strand breaks and interstrand crosslinks induced by X-rays and anti-tumor agents.
Xeroderma pigmentosum
A hereditary DNA repair disorder caused by mutations in genes involved in nucleotide-excision repair (NER), leading to hypersensitivity to sunlight/UV, increased skin cancer incidence, premature aging, and a life expectancy of 29–37 years.
Werner syndrome
A rare autosomal recessive disorder characterized by premature aging, retarded growth following normal growth until puberty, typical diagnosis around age 24, and a global incidence of 1:100,000.
Point mutation
A single-base change in DNA that can occur through base substitution, single-base insertion, or single-base deletion.
Silent mutation
A point mutation in which a nucleotide substitution alters a codon to synonymous codon that codes for the exact same amino acid, resulting in no change to the protein.
Nonsense mutation
A point mutation in which a base substitution creates a premature STOP codon, causing early termination of translation and producing a shortened polypeptide.
Conservative missense mutation
A point mutation in which a base substitution results in the incorporation of a different amino acid that possesses chemical properties similar to the original amino acid.
Non-conservative missense mutation
A point mutation in which a base substitution results in the incorporation of a different amino acid that possesses distinct chemical properties compared to the original amino acid.
Frameshift mutation
A mutation caused by an insertion or deletion of nucleotides not divisible by three, altering how downstream codons are grouped and read during translation and changing the amino acid sequence.
In-frame insertion or deletion
A small-scale indel involving a multiple of three nucleotides added or removed from coding DNA, which preserves the translational reading frame (e.g., ΔF508 in cystic fibrosis).
Chromosomal inversion
A large-scale chromosomal mutation in which a chromosome segment breaks, reverses orientation, and rejoins (e.g., inversion disrupting the F8 gene in Haemophilia A).
Chromosomal deletion
A large structural mutation in which an entire segment of a chromosome is lost, potentially removing multiple genes (e.g., deletion of part of chromosome 5p in Cri du chat syndrome).
Chromosomal duplication
A structural mutation where a chromosome segment is copied, potentially increasing gene dosage (e.g., HER2 amplification in certain cancers).
Chromosomal translocation
A structural mutation in which a broken chromosome segment attaches to a non-homologous chromosome (e.g., the Philadelphia chromosome in chronic myeloid leukaemia).
Copy-number variation (CNV)
A genomic alteration involving the loss or gain of a genomic segment, producing fewer or additional copies between individuals (e.g., AMY1 copy numbers or large BRCA1/2 rearrangements).
Single nucleotide polymorphism (SNP)
A single-nucleotide difference occurring at a defined genomic position that is common within a population, representing the most frequent type of human genetic variation.
Tandem-repeat polymorphism
A genetic variation characterized by differences in the number of repeated sequence units between individuals, commonly utilized in forensic DNA profiling.
CYP2C9*1
The wild-type allele of the cytochrome P450 2C9 gene with no amino acid change and normal enzyme activity, breaking down warfarin at the usual rate.
CYP2C9*2
An allelic variant of CYP2C9 featuring a C→T DNA change that produces an Arg144Cys substitution, causing reduced enzyme activity and slower warfarin breakdown.
CYP2C9*3
An allelic variant of CYP2C9 featuring an A→C DNA change that produces an Ile359Leu substitution, resulting in a greater reduction in enzyme activity than *2 and slower warfarin breakdown.
Heterozygote advantage
An evolutionary phenomenon in which heterozygous individuals carrying one disease-associated allele experience a survival benefit against an environmental disease compared to non-carriers.
Sickle cell heterozygote advantage
The survival benefit wherein carrying one HbS allele in the HBB gene confers resistance to malaria caused by Plasmodium falciparum, maintaining high allele frequency in sub-Saharan Africa, India, and the Mediterranean.
Beta-Thalassemia heterozygote advantage
The phenomenon in which carriers of HBB mutations gain resistance to malaria and potentially lower arterial blood pressure, found at high frequencies in the Mediterranean, Middle East, and parts of Asia and Africa.
Tay-Sachs disease heterozygote advantage
The hypothesized selective benefit wherein carriers of HEXA gene mutations have possible partial resistance to tuberculosis (TB), seen at higher frequencies in Ashkenazi Jewish populations.
Phenylketonuria (PKU) heterozygote advantage
The protective benefit where slightly elevated phenylalanine in PAH mutation carriers protects against the fungal toxin ochratoxin A (linked to miscarriage), maintaining higher carrier frequency in European populations.
Pathogenic
A clinical variant classification applied when evidence supports a confirmed disease-causing role.
Likely pathogenic
A clinical variant classification defined by having greater than 90% probability of being disease-causing.
Variant of uncertain significance (VUS)
A clinical variant classification applied when available evidence regarding pathogenicity is insufficient or conflicting.
Likely benign
A clinical variant classification defined by having greater than 90% probability of not causing the condition being assessed.
Benign
A clinical variant classification applied when evidence supports that the variant does not cause the condition being assessed.
Mutation
The biological process by which a new DNA sequence change arises from an uncorrected replication error or DNA damage that becomes fixed in the sequence, or the resulting sequence change itself.
Polymorphism
A traditional population-genetics term for a DNA sequence variant that reaches an allele frequency of at least 1% in a population.
Variant
A neutral umbrella term used for any difference from a reference DNA sequence, regardless of its population frequency or biological consequence.